Patent application number | Description | Published |
20100291678 | Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses - Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4 | 11-18-2010 |
20110052547 | RAPAMYCIN-RESISTANT T CELLS AND THERAPEUTIC USES THEREOF - Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer. | 03-03-2011 |
20120034249 | Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 02-09-2012 |
20120207727 | Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses - Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4 | 08-16-2012 |
20120263693 | Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 10-18-2012 |
20130071409 | ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells - The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents. | 03-21-2013 |
Patent application number | Description | Published |
20130287748 | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 10-31-2013 |
20130288368 | Compositions for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 10-31-2013 |
20130309258 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 11-21-2013 |
20140106449 | Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 04-17-2014 |
20140370017 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 12-18-2014 |
20150050729 | Compositions for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 02-19-2015 |
20150093822 | Compositions for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 04-02-2015 |
20150099299 | Compositions for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 04-09-2015 |
20150118202 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain | 04-30-2015 |
20150140019 | Compositions and Methods for Regulating CAR T Cells - The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell. | 05-21-2015 |
20150190428 | Methods for Assessing the Suitability of Transduced T Cells for Administration - The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject. | 07-09-2015 |
20150202286 | Toxicity Management for Anti-Tumor Activity of CARs - The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient. | 07-23-2015 |
20150290244 | USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE - The present invention provides compositions and methods for inducing tolerance in a human. The invention includes administering a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 10-15-2015 |
20150342994 | ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells - The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents. | 12-03-2015 |
20160000829 | METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 01-07-2016 |
Patent application number | Description | Published |
20090211570 | PROCESS FOR MAKING ENZYME-RESISTANT STARCH FOR REDUCED-CALORIE FLOUR REPLACER - An enzyme resistant starch type III having a melting point or endothermic peak of at least about 140° C. as determined by differential scanning calorimetry (DSC) is produced in yields of at least about 25% by weight, based upon the weight of the original starch ingredient. A gelatinization stage, nucleation/propagation stage, and preferably a heat-treatment stage are used to produce reduced calorie starch-based compositions which contain the enzyme resistant starch type III. The high melting point of the enzyme resistant starch permits its use in baked good formulations without substantial loss of enzyme resistance upon baking. A gelatinized, starch-based bulking agent having at least 30% by weight of the enzyme-resistant starch may be used in bar-type, extruded, sheeted, or rotary molded food products. The melting enthalpy of the bulking agent may be from about 0.5 to about 4 Joules/g and its water-holding capacity may be less than 3 grams. | 08-27-2009 |
20100080883 | PRODUCTION OF LOW CALORIE, EXTRUDED, EXPANDED FOODS HAVING A HIGH FIBER CONTENT - An extruded, directly expanded, high fiber reduced calorie food product, such as a ready-to-eat (RTE) cereal or sweet or savory snack, is produced at high production rates without substantial loss of extrusion functionality and extrudability by replacing a substantial portion of at least one flour with a gelatinized, enzyme-resistant starch type III ingredient or bulking agent as a reduced-calorie, high fiber flour replacer. The resistant starch type III ingredient or bulking agent contains an enzyme-resistant starch type III having a melting point with an endothermic peak temperature of at least about 140° C., and may have a water-holding capacity of less than 3 grams water per gram of the starch-based bulking agent. The total dietary fiber retention of the gelatinized, starch-based bulking agent may be at least about 90% by weight after the extrusion using a die temperature of least about 100° C., and a die pressure of at least about 150 psig. | 04-01-2010 |
20110293788 | Process for Making Enzyme-Resistant Starch for Reduced-Calorie Flour Replacer - An enzyme resistant starch type III having a melting point or endothermic peak of at least about 140° C. as determined by differential scanning calorimetry (DSC) is produced in yields of at least about 25% by weight, based upon the weight of the original starch ingredient. A gelatinization stage, nucleation/propagation stage, and preferably a heat-treatment stage are used to produce reduced calorie starch-based compositions which contain the enzyme resistant starch type III. The high melting point of the enzyme resistant starch permits its use in baked good formulations without substantial loss of enzyme resistance upon baking. A gelatinized, starch-based bulking agent having at least 30% by weight of the enzyme-resistant starch may be used in bar-type, extruded, sheeted, or rotary molded food products. The melting enthalpy of the bulking agent may be from about 0.5 to about 4 Joules/g and its water-holding capacity may be less than 3 grams. | 12-01-2011 |
20120276268 | PRODUCTION OF LOW CALORIE, EXTRUDED, EXPANDED FOODS HAVING A HIGH FIBER CONTENT - Extruded, directly expanded, high fiber reduced calorie food products, such as a ready-to-eat (RTE) cereal or sweet or savory snack, are produced at high production rates without substantial loss of extrusion functionality and extrudability by replacing a substantial portion of at least one flour with a gelatinized, enzyme-resistant starch type III ingredient or bulking agent as a reduced-calorie, high fiber flour replacer. The resistant starch type III ingredient or bulking agent contains an enzyme-resistant starch type III having a melting point with an endothermic peak temperature of at least about 140° C., and may have a water-holding capacity of less than 3 grams water per gram of the starch-based bulking agent. The total dietary fiber retention of the gelatinized, starch-based bulking agent may be at least about 90% by weight after extrusion using a die temperature of least about 100° C., and a die pressure of at least about 150 psig. | 11-01-2012 |
20130040027 | MEAT-CONTAINING, STRIP SHAPED FOOD PRODUCT AND METHOD OF MAKING SAME - A flexible, strip-shaped food product is made by comminuting substantially frozen meat and heating the comminuted meat to at least partially denature the meat proteins and cooling the cooked meat. About 4% by weight to about 45% by weight of wheat flour is admixed with the cooked meat, along with other ingredients, to form a dough. Use of the wheat flour unexpectedly increases tensile strength of the dough and products baked from the dough, and maintains flexibility of the strip-shaped food products over an extended period of time. Cooking of the meat in the presence of salt unexpectedly increases water activity of the pieces, resulting in a product that has a skin and a moist middle, while maintaining tensile strength. The dough is rotary-molded into strip-shaped pieces. The rotary mold may have angled die cups. The strip-shaped dough pieces are then baked and dried. | 02-14-2013 |
20130078358 | STIGMASTEROL-RICH PHYTOSTEROL COMPOSITION AND USE - A stigmasterol-rich phytosterol composition is prepared wherein the composition comprises at least 50% stigmasterol, based on the total weight of phytosterols, no more than 1000 ppm water, no more than 50 ppm ethanol, and wherein stigmasterol is at least 98% in the anhydrous form. A ready-to-freeze beverage is provided comprising the stigmasterol-rich composition and water, with optional additives. A frozen beverage is prepared from the ready-to-freeze beverage as a pourable slush. There are further provided processes to prepare the ready-to-freeze beverage and the frozen slush beverage. | 03-28-2013 |
Patent application number | Description | Published |
20080210846 | DRIVEN LIGHT SHIELD FOR IMAGERS - An actively driven, metal light shield for shielding floating diffusion regions and amplifiers of multi-port CCD or CMOS imager arrays from unwanted light is disclosed. The driven shield overlies one or more floating diffusion regions and buffer amplifiers lying outside the active pixel area of the imager (non-imaging area), which is also protected from unwanted light by a fixed potential shield. The driven shield is directly electrically connected to a source node of a source-follower amplifier stage, i.e., the buffer amplifiers non-inverting output. The fixed potential shield is electrically connected to a DC voltage capable of eliminating charging of the fixed potential shield and substantially overlies the non-imaging area and at least partially overlapping the driven shield. The voltage on the source-follower output follows the voltage impressed on the floating diffusion region capacitance which then drives the driven shield, thereby reducing parasitic capacitance added by the fixed potential shield to floating diffusion regions by about an order of magnitude, which improves the ratio of output voltage of the floating diffusion regions to applied charge. Separate driven shields can also be applied to subsequent stages of source follower amplifiers to reduce parasitic capacitance induced by the fixed potential shield. | 09-04-2008 |
20090298260 | BACK-ILLUMINATED IMAGER USING ULTRA-THIN SILICON ON INSULATOR SUBSTRATES - A method for fabricating a back-illuminated semiconductor imaging device on an ultra-thin semiconductor-on-insulator substrate (UTSOI) is disclosed. The UTSOI substrate is formed by providing a handle wafer comprising a mechanical substrate and an insulator layer substantially overlying the mechanical substrate. A donor wafer is provided. Hydrogen is implanted in the donor wafer to form a bubble layer. The donor wafer is doped with at least one dopant to form a doped layer proximal to the bubble layer. The handle wafer and the donor wafer are bonded between the insulator layer of the handle wafer and a surface of the donor wafer proximal to the doped layer to form a combined wafer having a portion substantially underlying the bubble layer. The portion of the combined wafer substantially underlying the bubble layer is removed so as to expose a seed layer. An epitaxial layer is grown substantially overlying the seed layer, wherein at least one dopant diffuse into the epitaxial layer. At the completion of the growing of the epitaxial layer, there exists a net dopant concentration in the seed layer and the epitaxial layer which has maximum value at or near an interface between the seed layer and the insulator layer. | 12-03-2009 |
20100200944 | DARK CURRENT REDUCTION IN BACK-ILLUMINATED IMAGING SENSORS - A method for fabricating a back-illuminated semiconductor imaging device on a semiconductor-on-insulator substrate, and resulting imaging device is disclosed. The device includes an insulator layer; a semiconductor substrate, having an interface with the insulator layer; an epitaxial layer grown on the semiconductor substrate by epitaxial growth; and one or more imaging components in the epitaxial layer in proximity to a face of the epitaxial layer, the face being opposite the interface of the semiconductor substrate and the insulator layer, the imaging components comprising junctions within the epitaxial layer; wherein the semiconductor substrate and the epitaxial layer exhibit a net doping concentration having a maximum value at a predetermined distance from the interface of the insulating layer and the semiconductor substrate and which decreases monotonically on both sides of the profile from the maximum value within a portion of the semiconductor substrate and the epitaxial layer. The doping profile between the interface with the insulation layer and the peak of the doping profile functions as a “dead band” to prevent dark current carriers from penetrating to the front side of the device. | 08-12-2010 |
20110290983 | CMOS IMAGER WITH COMPANDED COLUMN SIGNALS - A non-linear conversion capability within an on-chip, per-column analog-to-digital converter (ADC) is provided to expand a compressed analog signal such that the resulting digital output that has a predetermined (linear or non-linear) mapping with respect to input brightness level of an incoming light signal to a row of pixels. The predetermined mapping may also be provided by a non-linear amplifier coupled to a linear or non-linear ADC and a resulting compressed non-linear digital representation at the output of the ADC is substantially linearized by an on-chip or an off-chip look-up table (LUT). | 12-01-2011 |
20120056079 | HIGH DYNAMIC RANGE CMOS PIXEL AND METHOD OF OPERATING SAME - A method of operating a CMOS pixel is disclosed. The CMOS pixel includes a photodiode (PPD), a transfer gate coupled to the PPD, and an anti-blooming drain coupled to the transfer gate. A potential barrier is formed between a potential well underlying the PPD and the transfer gate. Charge is accumulated in the potential well in response to electromagnetic radiation during a first integration time. Excess charge is removed from the potential well to the anti-blooming drain that exceeds the first potential barrier. A size of the potential barrier is increased. Charge is accumulated in the potential well during a second integration time. | 03-08-2012 |
20120056080 | High Dynamic Range CMOS Pixel and Method of Operating Same - A method of operating a CMOS pixel is disclosed. The CMOS pixel includes a photodiode (PPD), a transfer gate coupled to the PPD, and an anti-blooming drain coupled to the transfer gate. A potential barrier is formed between a potential well underlying the PPD and the transfer gate. Charge is accumulated in the potential well in response to electromagnetic radiation during a first integration time. Excess charge is removed from the potential well to the anti-blooming drain that exceeds the first potential barrier. A size of the potential barrier is increased. Charge is accumulated in the potential well during a second integration time. | 03-08-2012 |
20120104464 | P-PIXEL CMOS IMAGERS USING ULTRA-THIN SILICON ON INSULATOR SUBSTRATES (UTSOI) - A CMOS image sensor is disclosed. The CMOS image sensor includes a semiconductor substrate having a surface. An epitaxial layer is grown on the surface. A p-type CMOS pixel formed substantially in the epitaxial layer. In one version of the CMOS image sensor, there exists a net n-type dopant concentration profile in the semiconductor substrate and the epitaxial layer which has a maximum value at a predetermined distance from the surface and which decreases monotonically on both sides of the profile from the maximum value within the semiconductor substrate and the epitaxial layer. In another version of the CMOS image sensor, there exists a net n-type dopant concentration profile in the semiconductor substrate and the epitaxial layer which has a maximum value at the surface and which decreases monotonically with increasing distance from the surface within the semiconductor substrate and the epitaxial layer. | 05-03-2012 |
20120190150 | DARK CURRENT REDUCTION IN BACK-ILLUMINATED IMAGING SENSORS - A back-illuminated semiconductor imaging device on a semiconductor-on-insulator substrate is disclosed. The device includes an insulator layer, a semiconductor substrate having an interface with the insulator layer, an epitaxial layer grown on the semiconductor substrate by epitaxial growth; and one or more imaging components in the epitaxial layer. The semiconductor substrate and the epitaxial layer exhibit a net doping concentration profile having a maximum value at a predetermined distance from the interface which decreases monotonically on both sides of the profile. The doping profile between the interface with the insulation layer and the peak of the doping profile functions as a “dead band” to prevent dark current carriers from penetrating to the front side of the device. | 07-26-2012 |
20140097328 | LOW POWER WIDE DYNAMIC RANGE CMOS IMAGER OUTPUT CIRCUIT - An imager has an array of pixels arranged in rows and columns, readout circuitry electrically coupled to the columns to receive signals from the pixels, the readout circuitry having at least one signal path with gain switching, and a threshold detector electrically coupled to the readout circuitry to set a gain to be applied by the readout circuitry. | 04-10-2014 |
Patent application number | Description | Published |
20100038289 | METAL SULPHONATE ADDITIVES FOR FOULING MITIGATION IN PETROLEUM REFINERY PROCESSES - The present application provides a method for reducing fouling, including particulate-induced fouling, in a hydrocarbon refining process including the steps of providing a crude hydrocarbon for a refining process; adding an additive selected from: | 02-18-2010 |
20100038290 | POLYALKYL SUCCINIC ACID DERIVATIVES AS ADDITIVES FOR FOULING MITIGATION IN PETROLEUM REFINERY PROCESSES - The present application provides a method for reducing fouling, including particulate-induced fouling, in a hydrocarbon refining process including the steps of providing a crude hydrocarbon for a refining process; adding a polyalkyl succinic acid derivative additive. The additive can be complexed with a boronating agent, such as boric acid, to yield a boron-containing polyalkyl succinic acid derivative. | 02-18-2010 |
20100147739 | ADDITION OF HIGH MOLECULAR WEIGHT NAPHTHENIC TETRA-ACIDS TO CRUDE OILS TO REDUCE WHOLE CRUDE OIL FOULING - High molecular weight naphthenic tetra-acids are added to a base crude oil to prevent and/or reduce fouling of crude oil refinery equipment. The method includes adding an effective amount of a high molecular weight naphthenic tetra-acid to the base crude oil to form a crude oil mixture and feeding the crude oil mixture to a crude oil refinery component. Particularly, the high molecular weight naphthenic tetra-acids include ARN acids. | 06-17-2010 |
20100160680 | PROCESS FOR THE EXTRACTION OF HIGH MOLECULAR WEIGHT NAPHTHENIC ACIDS FROM CALCIUM NAPHTHENATE SALTS - A method for recovering high molecular weight naphthenic tetra-acids, particularly ARN acids from a calcium naphthenate deposit. Calcium naphthenate deposits contain large amounts of calcium naphthenate salts of ARN acids. The method dual solvent extraction process in which the naphthenic tetra-acids chemically bound as calcium naphthenate salts are converted into free acid monomers by an aqueous acid. The resulting free acid monomers are then dissolved into an organic solvent phase and the counterions dissolve in the aqueous acid phase. The naphthenic tetra-acids are then recovered from the organic solvent phase. | 06-24-2010 |
20100170829 | POLYALKYL SUCCINIC ANHYDRIDE DERIVATIVES AS ADDITIVES FOR FOULING MITIGATION IN PETROLEUM REFINERY PROCESSES - The present invention provides a method for reducing fouling, including particulate-induced fouling, in a hydrocarbon refining process including the steps of providing a crude hydrocarbon for a refining process; adding at least one polyalkyl succinic anhydride derivative additive disclosed herein. The additive can be complexed with a boronating agent, such as boric acid, to yield a boron-containing polyalkyl succinic anhydride derivative. | 07-08-2010 |
20110139687 | METHOD AND SYSTEMS TO REMOVE POLAR MOLECULES FROM REFINERY STREAMS - The present invention relates to methods and systems for removing polar molecule contaminants from a refinery stream in connection with the processing of hydrocarbon fluids, chemicals, whole crude oils, blends and fractions in refineries and chemical plants that include adding high surface energy and/or high surface area nanoparticle compounds to a refinery stream to remove the polar molecule contaminants. | 06-16-2011 |
20110147275 | POLYALKYLENE EPOXY POLYAMINE ADDITIVES FOR FOULING MITIGATION IN HYDROCARBON REFINING PROCESSES - The present invention provides a method for reducing fouling, including particulate-induced fouling, in a hydrocarbon refining process including the steps of providing a crude hydrocarbon for a refining process and adding an antifouling agent containing a polymer base unit and a polyamine group to the crude hydrocarbon. The antifouling agent can be obtained by reacting an epoxidation reagent with a vinyl-terminated polymer, such as polypropylene or poly(ethylene-co-propylene), to form a terminal epoxy group, followed by reacting a polyamine with the epoxy group. | 06-23-2011 |
20120330057 | PROCESS FOR THE EXTRACTION OF HIGH MOLECULAR WEIGHT NAPHTHENIC ACIDS FROM CALCIUM NAPHTHENATE SALTS - A method for recovering high molecular weight naphthenic tetra-acids, particularly ARN acids from a calcium naphthenate deposit. Calcium naphthenate deposits contain large amounts of calcium naphthenate salts of ARN acids. The method dual solvent extraction process in which the naphthenic tetra-acids chemically bound as calcium naphthenate salts are converted into free acid monomers by an aqueous acid. The resulting free acid monomers are then dissolved into an organic solvent phase and the counterions dissolve in the aqueous acid phase. The naphthenic tetra-acids are then recovered from the organic solvent phase. | 12-27-2012 |